drugset / Trial / NCT00057343

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

NCT00057343

Phase 3 Terminated 400 enrolled Biogen
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.

Timeline

Start
2003-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody
Subject ibritumomab tiuxetan Monoclonal antibody

Indications